Fanconi Anemia: Diagnostic Steps and Treatment Recommendations
Diagnosis
Confirm Fanconi anemia diagnosis through chromosomal breakage testing on blood lymphocytes using diepoxybutane (DEB) or mitomycin C (MMC), and if results are inconclusive or clinical suspicion remains high, proceed immediately to fibroblast testing to detect hematopoietic somatic mosaicism. 1, 2
Initial Diagnostic Workup
- Chromosomal breakage test is the screening diagnostic standard, measuring DNA breaks after exposure to DEB or MMC in blood T-cells 1
- Fibroblast analysis is essential when blood testing is inconclusive, as hematopoietic somatic mosaicism can mask FA diagnosis in blood samples—this detected 3 additional FA cases among 7 total diagnoses in a cohort of 87 bone marrow failure patients 2
- Flow cytometry-based MMC sensitivity test in fibroblasts provides a reliable alternative method for evaluating FA phenotype 2
- FANCD2-monoubiquitination assays serve as complementary diagnostic tools 2
- Genetic testing through germline sequencing identifies the specific complementation group and mutations, with FANCA mutations most common (60-70%), followed by FANCC (10-14%) and FANCG (8-10%) 1
Baseline Evaluation at Diagnosis
- Complete blood count (CBC) and bone marrow aspirate with biopsy to establish baseline hematologic status 1
- Physical examination focusing on congenital anomalies: abnormal skin pigmentation, short stature, skeletal malformations of upper limbs, thumb or radii abnormalities, renal anomalies, cardiac malformations, gonadal anomalies, ophthalmic manifestations 1
- Endocrine evaluation for growth hormone deficiency, hypothyroidism, and diabetes 1
Treatment and Management
Hematopoietic Stem Cell Transplantation (HSCT)
HSCT remains the only curative therapeutic option for bone marrow failure and should be performed in optimal conditions: when moderate cytopenia shifts to severe, prior to transfusion dependence, and before clonal evolution or myelodysplasia/AML develops. 3
- Timing is critical: Over 95% of FA patients develop bone marrow failure, with 40% developing severe BMF by age 20 and 50% by age 50; early intervention when an HLA-identical sibling donor is available improves outcomes 1, 4
- HLA-identical sibling transplants achieve 66% two-year survival compared to 29% with alternative donors 4
- Haploidentical HSCT offers very good outcomes as an alternative when matched sibling donors are unavailable 3
- Reduced-intensity conditioning is mandatory—standard myeloablative dosing causes major toxicity in FA patients due to DNA repair defects; use low-dose (15-25 mg/kg) cyclophosphamide plus limited field irradiation 1, 4
- Antithymocyte globulin and cyclosporine for GVHD prophylaxis are associated with increased survival 4
- Younger age and higher pretransplant platelet counts predict better outcomes 4
Non-Transplant Medical Management
- Androgen therapy may be attempted for bone marrow failure in patients not proceeding to immediate transplant 1
- Avoid DNA-damaging chemotherapy agents due to cellular hypersensitivity to interstrand cross-links 1
- Gene therapy remains experimental but shows promise when performed in early BMF phases with high numbers of corrected cells 3
Surveillance Protocol
Hematologic Monitoring
- CBC monitoring more frequently than annually to detect progressive cytopenias and MDS proactively 1
- Annual bone marrow aspirate and biopsy after initial diagnosis 1
- Risk assessment: 11% develop cancer at pediatric age; cumulative incidence by age 50 is approximately 50% for MDS, 10% for leukemia, and 20-30% for solid tumors 1
Cancer Screening
Begin comprehensive head and neck squamous cell carcinoma (HNSCC) surveillance in early adolescence, as solid tumor risk starts in late teens with median onset in the 20s-30s. 1
- Monthly oral self-examinations from diagnosis (with parental assistance for children) 1
- Biannual dental examinations (general inspection without X-rays unless specifically indicated, to minimize radiation exposure) 1
- Annual HNSCC evaluation by otolaryngologist experienced in oral cancer, beginning by age 16 years or early adolescence 1
- Annual gynecologic examination starting in adolescence for females 1
- HPV vaccination per AAP schedule for both boys and girls to reduce anogenital cancer risk 1
Special Considerations for High-Risk Subtypes
- FANCD1/BRCA2 or FANCN/PALB2 mutations: High risk of brain tumors (medulloblastoma) and Wilms tumor, particularly before age 6 years; patients with FANCD1/BRCA2 PV upstream or in exon 11 are highly susceptible to cancer from infancy 1
- Post-HSCT patients: Higher risk of solid tumors including HNSCC, kidney, liver, brain tumors, and breast cancers; intensified surveillance required 1
Non-Malignant Complications Monitoring
- Hepatic surveillance: Biannual hepatic ultrasounds and liver function tests every 3 months for patients on androgen therapy 1
- Endocrine monitoring: At least annual evaluation, particularly for patients on androgen therapy; common complications include hypothyroidism (42%), diabetes (10%), low bone mineral density (51%) 1, 5
- Pulmonary function tests: Baseline when patient can perform them, with individualized follow-up 1
Critical Pitfalls to Avoid
- Missing FA diagnosis in bone marrow failure patients: Always test fibroblasts if blood chromosomal breakage is inconclusive or negative but clinical suspicion remains, as somatic mosaicism can produce false-negative blood results 2
- Using standard-dose conditioning for HSCT: This causes catastrophic toxicity; always use reduced-intensity regimens 1, 4
- Delaying HSCT: Outcomes worsen with increasing age, lower platelet counts, transfusion dependence, and clonal evolution 4, 3
- Inadequate radiation protection: No amount of radiation is absolutely safe in FA; minimize diagnostic X-rays and use clinical inspection instead 1
- Overlooking carrier screening in families: Parents with rare FA subtypes (FANCD1/BRCA2, FANCJ/BRIP1, FANCN/PALB2, FANCO/RAD51C, FANCS/BRCA1, FANCU/XRCC2) have moderate adult-onset cancer risks and need screening 1